Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Trial Testing Nelfinavir, an Inhibitor of Akt Signaling, in Combination With Preoperative Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer

NCT00704600 is registered in ClinicalTrials.gov with Maastricht Radiation Oncology as lead sponsor.

NCT NCT00704600
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00704600 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Trial Testing Nelfinavir, an Inhibitor of Akt Signaling, in Combination With Preoperative Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer
Lead sponsor
Maastricht Radiation Oncology
Phase
Phase 1/2
Overall status
Completed
Start date
September 30, 2008
Completion date
July 31, 2013
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, colorectal carcinoma, colorectal tumors, neoplasms, colorectal